The rising prevalence of cardiovascular diseases (CVDs) in Mexico is a major driver for the angioplasty balloons market, as it directly increases the demand for interventional cardiac procedures. In recent years, Mexico has witnessed a growing burden of heart-related conditions such as coronary artery disease, atherosclerosis, and myocardial infarction, largely driven by lifestyle changes, sedentary habits, unhealthy dietary patterns, and increasing rates of obesity, diabetes, and hypertension. These risk factors are becoming more common across both urban and semi-urban populations, leading to a higher incidence of arterial blockages that require minimally invasive treatment.
Angioplasty using balloon catheters has become a preferred treatment option for restoring blood flow in narrowed or blocked coronary arteries, especially as it offers faster recovery compared to open-heart surgery. As the patient pool continues to expand, hospitals and cardiac centers are performing a higher number of angioplasty procedures, thereby increasing the consumption of angioplasty balloons. Additionally, growing awareness about early diagnosis and improved access to cardiac care facilities is further supporting procedure volumes. Overall, the increasing cardiovascular disease burden in Mexico is creating sustained and long-term demand for angioplasty balloon technologies across the healthcare system.
Access Full Report @ https://www.databridgemarketresearch.com/reports/mexico-angioplasty-balloons-market
Data Bridge market research analyzes that the Mexico Angioplasty Balloons Market size was valued at USD 38.99 million by 2033 from USD 27.73 million in 2025, growing with a CAGR of 4.4% during the forecast period of 2026 to 2033.
Key Findings of the Study
GROWING PUBLIC AWARENESS OF MINIMALLY INVASIVE SURGICAL TECHNIQUES
Growing public awareness of minimally invasive surgical techniques is significantly driving the Mexico Angioplasty Balloons Market. As patients become more informed about advanced treatment options, there is a noticeable shift in preference from traditional open-heart surgeries to less invasive procedures such as balloon angioplasty. These techniques offer key benefits including reduced hospital stay, lower risk of complications, minimal scarring, and faster recovery times, which are increasingly valued by both patients and healthcare providers. In Mexico, rising access to digital health information, social media awareness campaigns, and improved patient education initiatives by hospitals and cardiology associations are contributing to this trend. Additionally, physicians are actively recommending minimally invasive interventions due to their clinical effectiveness and improved post-operative outcomes.
This growing acceptance is further supported by the expansion of catheterization labs and availability of skilled interventional cardiologists across urban healthcare centers. As a result, demand for angioplasty balloons especially drug-coated and advanced balloon types is increasing steadily. Overall, heightened awareness is transforming treatment decisions, encouraging early intervention, and accelerating the adoption of angioplasty procedures in the Mexican cardiovascular care landscape.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2026 to 2033
|
|
Base Year
|
2025
|
|
Historic Years
|
2018-2024 (Customizable to 2013-2017)
|
|
Quantitative Units
|
Revenue in USD million
|
|
Segments Covered
|
By Type (Plain Old Balloon Angioplasty, Drug-Coated Balloon (DCB), Scoring Balloons, Cutting Balloons, Stent Graft Balloon Catheter, Others), Material (Nylon, Polyurethane, Silicone Urethane Co-Polymers, Polyethylene, Others), Balloon Type (Non-Compliant, Semi-Compliant, Compliant), Disease Indication (Coronary Angioplasty, Peripheral Angioplasty, Carotid Angioplasty, Renal Artery Angioplasty, Venous Angioplasty, Others), End User (Hospitals, Cath Labs, Ambulatory Surgery Centers (ASCs), Specialty Clinics, Diagnostic Centers, Others) Distribution Channel (Direct Tender, Retail Sales, Online Sales, Others)
|
|
Countries Covered
|
Mexico
|
|
Market Players Covered
|
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
Mexico Angioplasty Balloons Market is categorized into six notable segments which are based on type, material, balloon type, disease indication, end user, distribution channel.
- On the basis of Type, the Mexico Angioplasty Balloons Market is segmented into Plain Old Balloon Angioplasty, Drug-Coated Balloon (DCB), Scoring Balloons. Cutting Balloons, Stent Graft Balloon Catheter, and Others.
In 2025, the Plain Old Balloon Angioplasty segment is expected to dominate the market
In 2025, the Plain Old Balloon Angioplasty dominated with share of 37.50% due to its widespread clinical use, cost-effectiveness, and strong presence in public healthcare institutions where budget constraints favor conventional treatment options. Additionally, its versatility across multiple lesion types and procedural simplicity make it a preferred first-line intervention in a large volume of angioplasty procedures.
- On the basis of material, the Mexico Angioplasty Balloons Market is segmented Nylon, Polyurethane, Silicone Urethane Co-Polymers, Polyethylene, Others.
In 2025, the Nylon segment is expected to dominate the market
In 2025, the Nylon segment is dominating the market with share of 47.60% due to its superior tensile strength and high-pressure resistance, which enables precise and controlled balloon expansion in complex lesions. Additionally, its excellent balance between flexibility and durability enhances catheter trackability and procedural reliability, making it a preferred choice among interventional cardiologists.
- On the basis of balloon type, the Mexico Angioplasty Balloons Market is segmented into Non-Compliant, Semi-Compliant, Compliant.
In 2025, the Non-Compliant segment is expected to dominate the market
In 2025, the Non-Compliant segment is dominating the market with share of 44.54% due to its superior ability to deliver precise and high-pressure dilation in calcified and complex lesions, ensuring controlled expansion without over-stretching the vessel. Additionally, increasing adoption in advanced interventional procedures and preference among cardiologists for accurate lesion management further strengthens its market leadership.
- On the basis of Disease Indication, the Mexico Angioplasty Balloons Market is segmented into Coronary Angioplasty, Peripheral Angioplasty, Carotid Angioplasty, Renal Artery Angioplasty, Venous Angioplasty, Others.
In 2025, the Coronary Angioplasty segment is expected to dominate the market
In 2025, the Coronary Angioplasty segment is dominating the market with share of 41.50% due to the high prevalence of coronary artery disease in Mexico, driven by increasing rates of diabetes, obesity, and hypertension. Additionally, the widespread adoption of percutaneous coronary interventions in both public and private hospitals significantly contributes to higher procedural volumes within this segment.
- On the baisis of End User, the Mexico Angioplasty Balloons Market is segmented into Hospitals, Cath Labs, Ambulatory Surgery Centers (ASCs), Specialty Clinics, Diagnostic Centers, Others.
In 2025, the Hospitals segment is anticipated to dominate the market
In 2025, the Hospitals segment is dominating the market with share of 47.50% due to the high volume of interventional cardiology procedures performed in both public and private hospital settings, supported by the availability of advanced infrastructure and skilled cardiologists. Additionally, hospitals serve as primary treatment centers for complex cardiovascular cases, ensuring consistent demand for angioplasty balloon devices across Tier I, Tier II, and Tier III facilities.
- On the basis of distribution Channel, the Mexico Angioplasty Balloons Market is segmented into Direct Tender, Retail Sales, Online Sales, Others.
In 2025, the Direct Tender segment is anticipated to dominate the market
In 2025, the Direct Tender segment is dominating the market with share of 71.70% to the high procurement volume of angioplasty devices by public healthcare institutions through centralized purchasing systems, ensuring cost efficiency and standardized supply. Additionally, government hospitals and large healthcare networks prefer direct tendering to secure bulk contracts from established medical device manufacturers, supporting consistent availability and pricing control.
Major Players
Boston Scientific Corporation (U.S.), Medtronic (Ireland), Abbott (U.S.), Terumo Corporation (Japan), B. Braun Medical (India) Pvt. Ltd. (India)
Market Developments
- In April 2026, Boston Scientific Corporation announced its first-quarter 2026 results on its official website, reporting net sales of USD 5.203 billion with strong growth across cardiovascular, MedSurg, and neuromodulation segments, while also highlighting continued advancement of its clinical pipeline and category leadership strategy; the development reflects the company’s focus on driving innovation, expanding global market presence, and strengthening its differentiated product portfolio, indirectly supporting growth momentum in interventional cardiology and minimally invasive device markets through sustained R&D investment and improved clinical outcomes.
- In April 2026, Medtronic announced CE Mark approval for its Stealth AXiS™ surgical system on its official website, enabling expansion of its integrated planning, navigation, and robotics platform across Europe; the development strengthens the company’s advanced surgical technology portfolio, enhances access to minimally invasive procedures, and supports precision-driven surgical outcomes through AI-enabled navigation and robotic-assisted capabilities, reinforcing Medtronic’s innovation leadership in image-guided and robotic surgery solutions.
- In March 2026, Abbott Laboratories completed the acquisition of Exact Sciences, as announced on its official website, expanding its presence in the oncology diagnostics market and adding a high-growth cancer screening business to its portfolio; the development strengthens the company’s diagnostics segment, enhances its capabilities in early disease detection, and supports long-term growth through portfolio diversification and expansion into advanced molecular and cancer diagnostic technologies.
- In April 2026, Terumo announced the renaming of the business segment operated by OrganOx to “Terumo Organ Technologies,” as published on its official website, aligning the segment within its broader corporate structure; the development strengthens the company’s strategic positioning in organ transplantation technologies, enhances portfolio integration, and supports long-term growth by expanding its presence in advanced therapeutic and life-saving medical solutions.
- In February 2026, B. Braun Medical (India) Pvt. Ltd. was ranked 1st as a ‘Dream Company to Work For’ 2026 by the World HRD Congress™, as announced on its official website; the development highlights the company’s strong workplace culture, employee-centric practices, and values-driven operations, strengthening its employer brand and supporting long-term organizational growth through talent development, innovation, and enhanced workforce engagement.
As per Data Bridge Market Research analysis:
For more detailed information about the Mexico Angioplasty Balloons Market report, click here – https://www.databridgemarketresearch.com/reports/mexico-angioplasty-balloons-market
